AI-guided treatment planning for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial uses artificial intelligence to create a digital twin of your cancer and simulate how it might respond to treatment. It aims to personalize your care and improve outcomes for people with locally advanced esophageal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with locally advanced squamous cell esophageal cancer in the chest area.
- You have not received any previous treatment for your cancer, such as chemotherapy, radiation, or immunotherapy.
- Your cancer is considered operable, and you are healthy enough for surgery.
- Your blood tests show adequate bone marrow, liver, and kidney function.
- You have a good performance status (able to care for yourself and be up and about).
- You are willing to use contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence (AI) to help plan personalized treatment for esophageal cancer by combining images and tissue samples. It aims to improve care by guiding doctors to choose the best therapy for each person.
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial tests a personalized treatment approach for advanced esophageal cancer that has stopped responding to immunotherapy. It aims to find better options for people whose cancer has progressed after standard treatments.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.